Spiegelberg D - Search Results

1

Higher Risk of Recurrence in Patients Treated for Head and Neck Cancer with Low BMI and Elevated Levels of C-Reactive Protein.

Spiegelberg D, Malmberg C, Tiblom Ehrsson Y, Laurell G. Spiegelberg D, et al. Cancers (Basel). 2022 Oct 21;14(20):5161. doi: 10.3390/cancers14205161. Cancers (Basel). 2022. PMID: 36291945 Free PMC article.

2

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.

Mortensen ACL, Berglund H, Hariri M, Papalanis E, Malmberg C, Spiegelberg D. Mortensen ACL, et al. Among authors: spiegelberg d. Sci Rep. 2023 Oct 6;13(1):16844. doi: 10.1038/s41598-023-43486-z. Sci Rep. 2023. PMID: 37803074 Free PMC article.

3

CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.

Spiegelberg D, Nilvebrant J. Spiegelberg D, et al. Contrast Media Mol Imaging. 2017 Jun 20;2017:2709547. doi: 10.1155/2017/2709547. eCollection 2017. Contrast Media Mol Imaging. 2017. PMID: 29097914 Free PMC article. Review.

4

The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells.

Mortensen ACL, Spiegelberg D, Brown CJ, Lane DP, Nestor M. Mortensen ACL, et al. Among authors: spiegelberg d. Front Oncol. 2019 Sep 19;9:923. doi: 10.3389/fonc.2019.00923. eCollection 2019. Front Oncol. 2019. PMID: 31616635 Free PMC article.

5

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.

Mortensen ACL, Mohajershojai T, Hariri M, Pettersson M, Spiegelberg D. Mortensen ACL, et al. Among authors: spiegelberg d. Front Oncol. 2020 Sep 30;10:532285. doi: 10.3389/fonc.2020.532285. eCollection 2020. Front Oncol. 2020. PMID: 33102211 Free PMC article.

6

A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties.

Spiegelberg D, Stenberg J, Haylock AK, Nestor M. Spiegelberg D, et al. Nucl Med Biol. 2016 Jan;43(1):12-18. doi: 10.1016/j.nucmedbio.2015.09.004. Epub 2015 Sep 21. Nucl Med Biol. 2016. PMID: 26702782 Free article.

7

The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model.

Spiegelberg D, Mortensen ACL, Palupi KD, Micke P, Wong J, Vojtesek B, Lane DP, Nestor M. Spiegelberg D, et al. Front Oncol. 2020 Sep 11;10:1717. doi: 10.3389/fonc.2020.01717. eCollection 2020. Front Oncol. 2020. PMID: 33014851 Free PMC article.

8

The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy.

Ingelshed K, Spiegelberg D, Kannan P, Påvénius L, Hacheney J, Jiang L, Eisinger S, Lianoudaki D, Lama D, Castillo F, Bosdotter C, Kretzschmar WW, Al-Radi O, Fritz N, Villablanca EJ, Karlsson MCI, Wermeling F, Nestor M, Lane DP, Sedimbi SK. Ingelshed K, et al. Among authors: spiegelberg d. Cancer Res Commun. 2022 Sep 28;2(9):1075-1088. doi: 10.1158/2767-9764.CRC-22-0053. eCollection 2022 Sep. Cancer Res Commun. 2022. PMID: 36922937 Free PMC article.

9

The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.

Lundsten S, Spiegelberg D, Stenerlöw B, Nestor M. Lundsten S, et al. Among authors: spiegelberg d. Int J Oncol. 2019 Dec;55(6):1287-1295. doi: 10.3892/ijo.2019.4888. Epub 2019 Sep 30. Int J Oncol. 2019. PMID: 31638190 Free PMC article.

10

Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines.

Abramenkovs A, Hariri M, Spiegelberg D, Nilsson S, Stenerlöw B. Abramenkovs A, et al. Among authors: spiegelberg d. Transl Oncol. 2022 Dec;26:101543. doi: 10.1016/j.tranon.2022.101543. Epub 2022 Sep 18. Transl Oncol. 2022. PMID: 36126563 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page